ABCL-1635: Cardiovascular Adverse Event Reporting Patterns With CD19 CAR-T and CD20 × CD3 Bispecific Antibodies in Relapsed/Refractory Large B-Cell Lymphoma: A FAERS Disproportionality Analysis
Year: 2026
Type: article
Institutions: Heidelberg University, Klinikum Ludwigshafen, Akhtar Saeed Medical and Dental College, University of Medicine and Pharmacy of Craiova, Carol Davila University of Medicine and Pharmacy, Al-Quds University, University Medical Centre Mannheim, University of North Texas Health Science Center
Language: English
Subfield: Toxicology
Domain: Life Sciences
Keywords: cardiovascular adverse events, CD19 CAR T-cell therapy, CD20/CD3 bispecific antibody, relapsed/refractory large B-cell lymphoma, diffuse large B-cell lymphoma, axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, brexucabtagene autoleucel, epcoritamab, glofitamab, mosunetuzumab, pharmacovigilance, drug safety
Open Access status: closed
OpenAlex ID: W7204689444
